• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A commentary on 'Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study'.

作者信息

Zhao Xin, Mao Tianyang, Xie Qingyun, Gao Fengwei, Wu Hong

机构信息

Department of Hepato-Pancreato-Biliary Surgery, The People's Hospital of Leshan, Leshan.

Liver Transplantation Center, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, People's Republic of China.

出版信息

Int J Surg. 2024 Feb 1;110(2):1294-1295. doi: 10.1097/JS9.0000000000000891.

DOI:10.1097/JS9.0000000000000891
PMID:37983841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10871568/
Abstract
摘要

相似文献

1
A commentary on 'Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study'.关于“经动脉化疗栓塞术作为微血管侵犯的中期肝细胞癌术后辅助治疗的效果：一项多中心队列研究”的述评
Int J Surg. 2024 Feb 1;110(2):1294-1295. doi: 10.1097/JS9.0000000000000891.
2
A commentary on 'Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study'.对“经动脉化疗栓塞完全缓解后肝切除治疗中期肝细胞癌的生存获益：一项回顾性、多中心队列研究”的述评
Int J Surg. 2024 Apr 1;110(4):2442-2443. doi: 10.1097/JS9.0000000000001052.
3
Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate-stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study.经动脉化疗栓塞术作为伴有微血管侵犯的中期肝细胞癌术后辅助治疗的效果：一项多中心队列研究
Int J Surg. 2024 Jan 1;110(1):315-323. doi: 10.1097/JS9.0000000000000805.
4
Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis.术后辅助经动脉化疗栓塞改善微血管侵犯肝细胞癌患者的预后：一项系统评价和荟萃分析
Acta Radiol. 2020 Jun;61(6):723-731. doi: 10.1177/0284185119878357. Epub 2019 Oct 8.
5
Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score-Matched Study of 1,008 Patients.经动脉单纯栓塞与经动脉化疗栓塞治疗中期肝细胞癌的疗效比较：一项对1008例患者的倾向评分匹配研究
J Vasc Interv Radiol. 2025 Jan;36(1):41-49. doi: 10.1016/j.jvir.2024.09.005. Epub 2024 Sep 17.
6
Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: A multicenter study.微血管侵犯分级对接受辅助性经动脉化疗栓塞的肝细胞癌患者的生存有影响：一项多中心研究。
Eur J Surg Oncol. 2025 Apr 24;51(8):110102. doi: 10.1016/j.ejso.2025.110102.
7
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.中期肝细胞癌患者的管理：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2.
8
Balloon-occluded versus conventional transarterial chemoembolization for the treatment of early to intermediate stage hepatocellular carcinoma: a meta-analysis and trial sequential analysis.球囊闭塞与传统经动脉化疗栓塞治疗早期至中期肝细胞癌的Meta分析和试验序贯分析
BMC Cancer. 2025 Jul 1;25(1):1036. doi: 10.1186/s12885-025-14435-y.
9
Letter to the editor: Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study.致编辑的信：经动脉化疗栓塞完全缓解后肝切除对中期肝细胞癌的生存获益：一项回顾性、多中心、队列研究
Int J Surg. 2024 Jul 1;110(7):4409-4410. doi: 10.1097/JS9.0000000000001084.
10
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.

本文引用的文献

1
Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate-stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study.经动脉化疗栓塞术作为伴有微血管侵犯的中期肝细胞癌术后辅助治疗的效果：一项多中心队列研究
Int J Surg. 2024 Jan 1;110(1):315-323. doi: 10.1097/JS9.0000000000000805.
2
Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.辅助免疫检查点抑制剂与术后肝细胞癌（PREVENT）无复发生存率的提高相关：一项前瞻性、多中心队列研究。
J Gastroenterol. 2023 Oct;58(10):1043-1054. doi: 10.1007/s00535-023-02018-2. Epub 2023 Jul 14.
3
Adjuvant transarterial chemoembolization for intermediate-stage hepatocellular carcinoma with microvascular invasion.经动脉化疗栓塞术辅助治疗伴微血管侵犯的中期肝细胞癌
Br J Surg. 2023 Jul 17;110(8):913-916. doi: 10.1093/bjs/znac376.
4
A Prospective Study Using Propensity Score Matching to Compare Long-term Survival Outcomes After Robotic-assisted, Laparoscopic, or Open Liver Resection for Patients With BCLC Stage 0-A Hepatocellular Carcinoma.一项前瞻性研究，采用倾向评分匹配法比较机器人辅助、腹腔镜或开腹肝切除术治疗BCLC 0-A期肝细胞癌患者后的长期生存结局。
Ann Surg. 2023 Jan 1;277(1):e103-e111. doi: 10.1097/SLA.0000000000005380. Epub 2022 Jan 25.
5
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.替诺福韦与恩替卡韦治疗乙型肝炎病毒相关肝细胞癌切除术后复发的比较。
Hepatology. 2021 Feb;73(2):661-673. doi: 10.1002/hep.31289. Epub 2020 Nov 2.
6
Laparoscopic versus open liver resection for hepatocellular carcinoma: Case-matched study with propensity score matching.腹腔镜与开腹肝切除术治疗肝细胞癌的对比：倾向评分匹配病例对照研究。
J Hepatol. 2015 Sep;63(3):643-50. doi: 10.1016/j.jhep.2015.04.005. Epub 2015 Apr 12.
7
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.抗病毒治疗可提高肝细胞癌患者术后生存率：一项随机对照试验。
Ann Surg. 2015 Jan;261(1):56-66. doi: 10.1097/SLA.0000000000000858.